3SBio Inc., a leading biopharmaceutical company headquartered in China, has established itself as a key player in the biotechnology industry since its founding in 1993. With a strong operational presence across major regions in Asia, 3SBio focuses on the development, manufacturing, and marketing of innovative therapies, particularly in the fields of oncology, nephrology, and autoimmune diseases. The company is renowned for its core products, including recombinant human erythropoietin and other biologics, which are distinguished by their high quality and efficacy. Over the years, 3SBio has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. With a commitment to advancing healthcare, 3SBio continues to drive innovation and improve patient outcomes in the biopharmaceutical landscape.
How does 3sbio's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
3sbio's score of 24 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, 3sbio reported total carbon emissions of approximately 60,649,530 kg CO2e, with Scope 1 emissions at about 11,663,450 kg CO2e and Scope 2 emissions at approximately 48,986,080 kg CO2e. This marked an increase from 2022, where total emissions were about 45,896,560 kg CO2e, with Scope 1 at approximately 7,257,230 kg CO2e and Scope 2 at around 38,639,330 kg CO2e. Over the past few years, 3sbio's emissions have fluctuated, with total emissions recorded at approximately 50,274,940 kg CO2e in 2021 and about 47,720,880 kg CO2e in 2020. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment and improvement in their climate strategy. Overall, while 3sbio has made strides in tracking its emissions, the absence of formal reduction targets suggests an opportunity for enhanced climate action and accountability in the coming years.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Scope 1 | 5,960,680 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
Scope 2 | 42,724,590 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
3sbio is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.